Advice

following an abbreviated submission

tiotropium/olodaterol (Spiolto® Respimat®) is accepted for use within NHS Scotland.

Indication under review: maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Spiolto® Respimat® should be used in patients for whom tiotropium and olodaterol are appropriate choices of antimuscarinic and long-acting beta2-agonist respectively.

Tiotropium/olodaterol (Spiolto® Respimat®) is available at a lower cost than the individual inhalers given separately.
 

Download detailed advice107KB (PDF)

Download

Medicine details

Medicine name:
tiotropium/olodaterol (Spiolto Respimat)
SMC ID:
1099/15
Indication:
Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Pharmaceutical company
Boehringer Ingelheim Ltd
BNF chapter
Respiratory system
Submission type
Abbreviated
Status
Accepted
Date advice published:
09 November 2015